Literature DB >> 9674776

Comparison of valproate and phenobarbital treatment after status epilepticus in rats.

A R Bolanos1, M Sarkisian, Y Yang, A Hori, S L Helmers, M Mikati, P Tandon, C E Stafstrom, G L Holmes.   

Abstract

OBJECTIVE: To investigate the long-term effects of two widely used antiepileptic medications, valproate and phenobarbital, on learning and behavior in the kainic acid (KA) model of epilepsy.
BACKGROUND: Prior clinical and animal studies have demonstrated that phenobarbital administered during development may result in subsequent cognitive impairment. It is unclear whether these adverse effects of phenobarbital extend to other antiepileptic drugs.
METHODS: A convulsant dose of KA was administered to rats on postnatal day (P) 35. From P36-75 rats received daily injections of phenobarbital (PH), valproate (VPA), or saline and spontaneous seizure frequency was monitored with video recordings. After tapering of the drugs, the rats were tested in the water maze (a measure of visuospatial memory) and handling test (a measure of emotionality). Brains were then analyzed for histologic lesions.
RESULTS: KA caused status epilepticus in all the rats. In the PH- and saline-treated groups, there was impaired learning in the water maze, increased emotionality, recurrent seizures, and histologic lesions in the hippocampal areas CA3, CA1, and dentate hilus. However, VPA-treated rats had no spontaneous seizures, abnormalities in handling, or deficits in visuospatial learning, and had fewer histologic lesions than animals receiving KA alone.
CONCLUSIONS: The long-term consequences of AED treatment during development are related to the drug used. VPA treatment after KA-induced status epilepticus prevents many of the neurologic sequelae typically seen after KA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674776     DOI: 10.1212/wnl.51.1.41

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

Review 1.  Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research.

Authors:  Wolfgang Löscher; Claudia Brandt
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy.

Authors:  Amy R Brooks-Kayal; Kevin G Bath; Anne T Berg; Aristea S Galanopoulou; Gregory L Holmes; Frances E Jensen; Andres M Kanner; Terence J O'Brien; Vicky H Whittemore; Melodie R Winawer; Manisha Patel; Helen E Scharfman
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

Review 3.  Is epilepsy a preventable disorder? New evidence from animal models.

Authors:  Kathryn A Giblin; Hal Blumenfeld
Journal:  Neuroscientist       Date:  2010-06       Impact factor: 7.519

4.  Brief postnatal exposure to phenobarbital impairs passive avoidance learning and sensorimotor gating in rats.

Authors:  Samuel B Gutherz; Catherine V Kulick; Colin Soper; Alexei Kondratyev; Karen Gale; Patrick A Forcelli
Journal:  Epilepsy Behav       Date:  2014-08-12       Impact factor: 2.937

Review 5.  The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.

Authors:  Rafal M Kaminski; Michael A Rogawski; Henrik Klitgaard
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

6.  A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage.

Authors:  H Steve White; Anitha B Alex; Amanda Pollock; Naama Hen; Tawfeeq Shekh-Ahmad; Karen S Wilcox; John H McDonough; James P Stables; Dan Kaufmann; Boris Yagen; Meir Bialer
Journal:  Epilepsia       Date:  2011-12-09       Impact factor: 5.864

Review 7.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

Review 8.  Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy.

Authors:  Wolfgang Löscher
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

9.  Midazolam-ketamine dual therapy stops cholinergic status epilepticus and reduces Morris water maze deficits.

Authors:  Jerome Niquet; Roger Baldwin; Keith Norman; Lucie Suchomelova; Lucille Lumley; Claude G Wasterlain
Journal:  Epilepsia       Date:  2016-08-08       Impact factor: 5.864

10.  The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy.

Authors:  Ling-Hui Zeng; Nicholas R Rensing; Michael Wong
Journal:  J Neurosci       Date:  2009-05-27       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.